Cargando…
BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells
The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674362/ https://www.ncbi.nlm.nih.gov/pubmed/23681223 http://dx.doi.org/10.1038/cddis.2013.155 |
_version_ | 1782272361389621248 |
---|---|
author | Sharma, A Singh, K Mazumder, S Hill, B T Kalaycio, M Almasan, A |
author_facet | Sharma, A Singh, K Mazumder, S Hill, B T Kalaycio, M Almasan, A |
author_sort | Sharma, A |
collection | PubMed |
description | The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both apoptosis and autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and enhanced autophagy must coexist in cells dying in response to an apoptosis inducing therapeutic. However, in the drug-resistant cells that have an increased dependence on antiapoptotic proteins, whether autophagy is also inhibited remains unclear. Here, we examined the role of the BCL-2 family in regulating cell death and autophagy in leukemic cell lines and their derivative isogenic Fd-resistant (FdR) cells. MCL-1 degradation following Fd treatment freed the proapoptotic effectors BIM and BECN1, thus leading to cell death-associated autophagy in Fd-sensitive cells. However, in FdR cells, low BIM expression and BECN1 sequestration by MCL-1 prevented cell death. Consistently, in sensitive cells inhibition of apoptosis using siBIM and of both the early-phase autophagy nucleation steps by siBECN1, shATG7 or 3-methyladenine and the late-phase autophagy by shLAMP2, significantly reduced Fd-induced cell death. Paradoxically, FdR cells were addicted to basal autophagy, which was dependent on AMP-activated protein kinase (AMPK) but not BECN1. Moreover, in FdR cells, inhibition of autophagy by shLAMP2, but not siBECN1, enhanced cell death. The BH3-mimetic obatoclax released BIM and BECN1 from MCL-1 in Fd-sensitive and BECN1 from MCL-1 in FdR cells, and was effective at killing both Fd-sensitive and - resistant leukemic cells, including primary CLL cells. Therefore, a differential regulation of autophagy through BECN1 and AMPK signaling in Fd-sensitive and - resistant cells determines the different possible outcomes of autophagy inhibition. These findings suggest effective means to overcome Fd resistance by induction of BIM-dependent apoptosis and activation of BECN1-dependent autophagy. |
format | Online Article Text |
id | pubmed-3674362 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36743622013-06-06 BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells Sharma, A Singh, K Mazumder, S Hill, B T Kalaycio, M Almasan, A Cell Death Dis Original Article The purine analog fludarabine (Fd) is an essential therapeutic for chronic lymphocytic leukemia (CLL). Innate or acquired resistance to Fd is a significant clinical problem and is largely mediated by increased expression of BCL-2 family members. The antiapoptotic BCL-2 family proteins inhibit both apoptosis and autophagy, therefore, downregulation of antiapoptotic BCL-2 family proteins and enhanced autophagy must coexist in cells dying in response to an apoptosis inducing therapeutic. However, in the drug-resistant cells that have an increased dependence on antiapoptotic proteins, whether autophagy is also inhibited remains unclear. Here, we examined the role of the BCL-2 family in regulating cell death and autophagy in leukemic cell lines and their derivative isogenic Fd-resistant (FdR) cells. MCL-1 degradation following Fd treatment freed the proapoptotic effectors BIM and BECN1, thus leading to cell death-associated autophagy in Fd-sensitive cells. However, in FdR cells, low BIM expression and BECN1 sequestration by MCL-1 prevented cell death. Consistently, in sensitive cells inhibition of apoptosis using siBIM and of both the early-phase autophagy nucleation steps by siBECN1, shATG7 or 3-methyladenine and the late-phase autophagy by shLAMP2, significantly reduced Fd-induced cell death. Paradoxically, FdR cells were addicted to basal autophagy, which was dependent on AMP-activated protein kinase (AMPK) but not BECN1. Moreover, in FdR cells, inhibition of autophagy by shLAMP2, but not siBECN1, enhanced cell death. The BH3-mimetic obatoclax released BIM and BECN1 from MCL-1 in Fd-sensitive and BECN1 from MCL-1 in FdR cells, and was effective at killing both Fd-sensitive and - resistant leukemic cells, including primary CLL cells. Therefore, a differential regulation of autophagy through BECN1 and AMPK signaling in Fd-sensitive and - resistant cells determines the different possible outcomes of autophagy inhibition. These findings suggest effective means to overcome Fd resistance by induction of BIM-dependent apoptosis and activation of BECN1-dependent autophagy. Nature Publishing Group 2013-05 2013-05-16 /pmc/articles/PMC3674362/ /pubmed/23681223 http://dx.doi.org/10.1038/cddis.2013.155 Text en Copyright © 2013 Macmillan Publishers Limited http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Article Sharma, A Singh, K Mazumder, S Hill, B T Kalaycio, M Almasan, A BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title_full | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title_fullStr | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title_full_unstemmed | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title_short | BECN1 and BIM interactions with MCL-1 determine fludarabine resistance in leukemic B cells |
title_sort | becn1 and bim interactions with mcl-1 determine fludarabine resistance in leukemic b cells |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3674362/ https://www.ncbi.nlm.nih.gov/pubmed/23681223 http://dx.doi.org/10.1038/cddis.2013.155 |
work_keys_str_mv | AT sharmaa becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells AT singhk becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells AT mazumders becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells AT hillbt becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells AT kalayciom becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells AT almasana becn1andbiminteractionswithmcl1determinefludarabineresistanceinleukemicbcells |